Norway · Delayed Price · Currency is NOK Thor Medical ASA Earnings Call Transcripts
Fiscal Year 2025
-
AlphaOne remains on track for Q3 2025 production, supported by a NOK 850 million order backlog and strong market demand. The company is fully funded through ramp-up, with initial revenues validating technology and a clear path to profitability by 2027.
-
First commercial sales and major strategic agreements validate technology and market position. AlphaOne plant is fully funded, on schedule for 2026, and capacity was expanded by 40% after a successful capital raise. Revenue potential is strong, with a NOK 770 million order backlog and ambitious growth plans.
Fiscal Year 2024
-
Transitioned from pilot to commercial phase with Alpha One fully funded and construction set to begin. Secured key sales agreements, validated technology, and positioned to meet surging demand in a rapidly growing radiopharmaceuticals market.
-
The company aims to become a leading supplier of lead-212 for targeted alpha therapies, leveraging a proprietary, scalable, and environmentally friendly production process. With a $1 billion revenue ambition and global expansion plans, it is positioned to address the growing demand for radiopharmaceuticals and support the shift toward alpha-based cancer treatments.
-
Leadership transition and strategic focus on radiopharmaceuticals position the company for growth, with a pilot plant nearing completion and Fast Track scale-up planned. Financials show a loss but sufficient funding for current operations, while market conditions remain highly favorable.